PLXND1 and neoplasm: PLXND1, a key target in tumor-associated endothelial cells, is elevated in these cells but shows reduced expression in patients with pCR, suggesting a potential prognostic role; however, paradoxically, it may also indicate the reduced efficacy of PLXND1--targeted therapy in the pCR group [29].